What is BiomX?
BiomX operates at the intersection of synthetic biology and clinical medicine, focusing on the discovery and validation of proprietary bacterial targets. The company's core competency lies in its ability to customize phage compositions, providing a targeted alternative to traditional antibiotic treatments that often lack specificity. By focusing on the microbiome, BiomX is pioneering new therapeutic modalities for conditions such as atopic dermatitis, primary sclerosing cholangitis, and colorectal cancer.
The firm's market position is bolstered by its ability to translate complex biological insights into scalable clinical assets. As a clinical-stage entity, BiomX maintains a rigorous focus on validating its phage cocktails through systematic research and development, ensuring that its therapeutic candidates meet the stringent requirements of modern healthcare standards.
How much funding has BiomX raised?
BiomX has raised a total of $71.3M across 4 funding rounds:
Series A
$24M
Series B
$32M
Other Financing Round
$12M
Private Equity
$3.3M
Series A (2017): $24M with participation from Takeda Ventures, JJDC, and OrbiMed
Series B (2019): $32M, investors not publicly disclosed
Other Financing Round (2025): $12M supported by Cystic Fibrosis Foundation
Private Equity (2026): $3.3M, investors not publicly disclosed
Key Investors in BiomX
Takeda Ventures
The corporate venture arm of Takeda Pharmaceutical, focusing on investments in innovative healthcare companies that align with its therapeutic areas of gastroenterology, oncology, and neuroscience.
OrbiMed
A premier healthcare-dedicated investment firm that manages capital across the entire spectrum of the life sciences industry, from early-stage ventures to established commercial-stage companies.
Cystic Fibrosis Foundation
A non-profit organization dedicated to funding research and development efforts aimed at curing cystic fibrosis and improving the quality of life for those affected by the disease.
What's next for BiomX?
Looking ahead, the recent infusion of capital is expected to accelerate the clinical validation of the company's lead programs. The strategic focus remains on expanding the therapeutic reach of its phage technology, particularly in indications where conventional treatments have proven insufficient. As BiomX moves through its current lifecycle stage, the emphasis will likely shift toward optimizing manufacturing processes and strengthening its intellectual property portfolio.
The ongoing support from specialized healthcare investors and non-profit foundations highlights the critical nature of the company's mission. By maintaining a disciplined approach to capital deployment and clinical execution, BiomX is well-positioned to navigate the complexities of the biotech landscape and deliver meaningful outcomes for patients suffering from chronic, bacteria-associated diseases.
